演題詳細

ポスター / Poster

ポスター 23 (Poster 23) :低悪性度B細胞リンパ腫:ベンダムスチン

print

日程
2013年10月11日(金)
時間
16:50 - 17:50
会場
ポスター会場 / Poster (ロイトン札幌 3F ロイトンホールABCD)
座長・司会
瀧本 理修 (Rishu Takimoto):1
1:札幌医科大学医学部附属病院 腫瘍・血液内科
 
前へ戻る

Bendamustine with or without rituximab in the treatment of relapsed or refractory indolent lymphoma

演題番号 : PS-1-165

関本 悦子 (Etsuko Sekimoto):1、柴田 泰伸 (Hironobu Shibata):1、尾崎 修治 (Shuji Ozaki):1、重清 俊雄 (Toshio Shigekiyo):1

1:Department of Hematology, Tokushima Prefectural Central Hospital, Tokushima, Japan

 

Bendamustine is an alkylating agent consisting of three structural elements: a 2-chloroethylamine alkylating group; a butyric acid side chain; and a benzimidazole ring. Bendamustine alone or in combination with rituximab have shown high efficacy in relapsed or refractory indolent B-cell malignancies. We retrospectively evaluated the safety and efficacy of this agent in 15 patients with relapsed or refractory indolent B-cell lymphoma (7 follicular lymphoma, 6 mantle cell lymphoma, 1 nodal marginal zone B-cell lymphoma, and 1 splenic marginal zone lymphoma). There were 10 males and 5 females. The median age was 69 years old (ranged from 53 to 86). Treatment consisted of bendamustine 90-120mg/m2 on day 1 and 2 (3 follicular lymphoma and 2 mantle cell lymphoma) or rituximab 375mg/m2 on day 1 and bendamustine 90-120mg/m2 on day 2 and 3 (4 follicular lymphoma and 4 mantle cell lymphoma). The overall response rate was 67%(complete response in 6 follicular lymphoma and 3 mantle cell lymphoma, partial response in 1 mantle cell lymphoma) in 15 patients. Grade 3 or 4 neutropenia or thrombocytopenia were observed in 8 patients. Non-hematological toxicities included mild gastrointestinal events in 3, skin reactions in 2 and herpes zoster in 1. Our experience suggest that bendamustine in combination with rituximab was tolerable and effective for patients with refractory or relapsed low-grade B-cell lymphoma, and prophylactic use of acyclovir would be desirable for heavily pretreated patients.

前へ戻る